Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

Legha, S S; Ring, S; Eton, O; Bedikian, A; Buzaid, A C; Plager, C; Papadopoulos, N

Legha, S S; Ring, S; Eton, O; Bedikian, A; Buzaid, A C; Plager, C; Papadopoulos, N.

Affiliation

Legha SS; Division of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. slegha@notes.mdacc.tmc.edu

J Clin Oncol ; 16(5): 1752-9, 1998 May.

Article in En | MEDLINE | ID: mdl-9586888

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Melanoma/drug therapy; Melanoma/secondary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Cisplatin/administration & dosage; Cisplatin/adverse effects; Dacarbazine/administration & dosage; Dacarbazine/adverse effects; Disease Progression; Female; Humans; Interferon-alpha/administration & dosage; Interferon-alpha/adverse effects; Interleukin-2/administration & dosage; Interleukin-2/adverse effects; Male; Melanoma/mortality; Middle Aged; Survival Rate; Vinblastine/administration & dosage; Vinblastine/adverse effects

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Melanoma Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1998 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links